Anti-Inflammatory Agent and Body Weight Table 2. Comparisons of Anthropometry, Calorie Intake and Metabolic Changes between the Two Groups for 12 Weeks Variable Treatment (n = 12) Placebo (n = 7) p value Δ Bwt (kg) - 7.0 ± 0.9* - 4.6 ± 1.2* 0.167 Δ BMI (kg/m2) - 2.5 ± 0.3* - 1.5 ± 0.4* 0.120 Δ Wc (cm) - 7.3 ± 1.9* - 4.4 ± 1.0* 0.340 Δ FM (kg) - 4.1 ± 0.7* - 3.1 ± 0.7* 0.335 Δ F%M (%) - 2.4 ± 0.4* - 2.0 ± 0.5* 0.616 Δ FFM (kg) - 1.9 ± 0.6* - 1.4 ± 0.6* 0.682 Δ s-BP (mmHg) - 8.7 ± 4.6 - 1.7 ± 3.7 0.340 Δ d-BP (mmHg) - 5.1 ± 4.7 - 0.7 ± 5.2 0.482 Δ Glucose (mg/dL) 10.2 ± 3.3 4.2 ± 4.6 0.650 Δ TC (mg/dL) - 22.6 ± 18.6 - 8.4 ± 6.2 0.773 Δ HDLC (mg/dL) 7.4 ± 6.2 5.2 ± 1.7 0.837 Δ LDLC (mg/dL) - 12.8 ± 7.2* 3.1 ± 9.3 0.261 Δ TG (mg/dL) 164.5 ± 191.3 - 29.4 ± 16.9 0.711 Δ Insulin (μU/μL ) - 1.5 ± 2.0 -7.9 ± 3.8 0.261 Δ HOMA-IR - 0.16 ± 0.82 - 1.73 ± 0.82 0.261 Δ Caloriestotal (kcal) - 178.3 ± 93.3 - 113.5 ± 89.7 0.964 Δ Carbohydrate (g) - 1.0 ± 1.8 4.3 ± 1.9 0.083 Δ Fat (g) - 1.9 ± 2.0 - 2.1 ± 1.1 0.750 Δ Protein (g) 2.1 ± 1.1 - 0.3 ± 2.1 0.213 Δ, amount of change; BMI, body mass index; FM, fat mass; F%M, fat mass Percentage in body; FFM, fat free mass; s-BP, systolic blood pressure; d-BP, diastolic blood pressure; Glucose, fasting glucose; TC, total cholesterol; HDLC, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol; TG, triglyceride; TSH, thyroid stimulating hormone; ΔCaloriestotal, change in total calorie in- take; ΔCarbohydrate, change in carbohydrate intake; ΔFat, change in fat intake; ΔProtein, amount of protein intake changes. All data are expressed as mean ± standard error; p values from Mann-Whitney U test comparing changes between the two groups. *p < 0.05 by paired t test before and after the changes of each parameter in the same groups. Table 3. Comparisons of Changes in Inflammatory Markers between the Two Groups for 12 Weeks Variable Treatment (n = 12) Placebo (n = 7) p value Δ WBC (×103/μL) 0.03 ± 0.45 0.02 ± 0.35 0.482 Δ hsCRP (mg/dL) - 0.86 ± 0.86* - 0.21 ± 0.10 0.227 Δ Homocysteine (mg/dL) 3.84 ± 2.25 1.98 ± 1.29 0.902 Δ Fibrinogen (mg/dL) 25.16 ± 11.46 12.57 ± 25.01 0.773 Δ TNF-α (pg/mL) - 5.37 ± 2.56 - 6.20 ± 3.23 0.837 Δ Adiponectin (μg/mL) 0.72 ± 0.63* - 0.45 ± 0.53 0.227 Δ, amount of change; WBC, white blood cell; hsCRP, high-sensitivity C-reactive protein; TNF-α, tumor necrosis factor-α. All data are expressed mean ± standard error. p values from Mann-Whitney U test. *p < 0.05 by paired t test before and after the changes of each parameter in the same groups. Statistical analyses This study sample size was small, so we used non-paramet- ric comparison (Mann-Whitney U test) to see the difference between the two groups. We used an χ2 test to evaluate the rates of over 5% and 10% weight reduction between the two groups. All significant values were defined by p < 0.05 as determined by SPSS version 11.5 (SPSS, Chicago, IL, USA). RESULTS After random allocation according to age, BMI, 19 of 26 subjects (73%) completed the study. Twelve subjects (7 men and 5 women) were in the treatment group and seven sub- jects (6 men and 1 woman) were in the placebo group. The mean age was 39.58 ± 1.42 years in the treatment group and Yonsei Med J http://www.eymj.org Volume 52 Number 2 March 2011 245